Management of cutaneous metastases using electrochemotherapy

References

• Schwartz RA. Cutaneous metastatic disease. J Am Acad Dermatol 1995;33:161–82.
   PubMed Web of Science ®Google Scholar
• Rolz-Cruz G, Kim CC. Tumor invasion of the skin. Dermatol Clin 2008;26:89–102, viii.
   PubMed Web of Science ®Google Scholar
• Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: A retrospective study of 4020 patients. J Am Acad Dermatol 1993;29:228–36.
   PubMed Web of Science ®Google Scholar
• Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RC, Gilbert RA, . Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998;83:148–57.
   PubMed Web of Science ®Google Scholar
• Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, . Electrochemotherapy, An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Supplements 2006;4:3–13.
   Google Scholar
• Mir LM, Glass LF, Sersa G, Teissie J, Domenge C, Miklavcic D, . Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 1998;77:2336–42.
   PubMed Web of Science ®Google Scholar
• Gehl J. Electroporation: Theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 2003;177:437–47.
   PubMedGoogle Scholar
• Tounekti O, Pron G, Belehradek J, Jr., Mir LM. Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res 1993;53:5462–9.
   PubMed Web of Science ®Google Scholar
• Gehl J, Skovsgaard T, Mir LM. Enhancement of cytotoxicity by electropermeabilization: An improved method for screening drugs. Anticancer Drugs 1998;9:319–25.
   PubMed Web of Science ®Google Scholar
• Orlowski S, Belehradek J Jr, Paoletti C, Mir LM. Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 1988;37:4727–33.
   PubMed Web of Science ®Google Scholar
• Jaroszeski MJ, Dang V, Pottinger C, Hickey J, Gilbert R, Heller R. Toxicity of anticancer agents mediated by electroporation in vitro. Anticancer Drugs 2000;11:201–8.
   PubMed Web of Science ®Google Scholar
• Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J, Jr., Mir LM. Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer 1993;72:3694–700.
   PubMed Web of Science ®Google Scholar
• Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL, Chiarion-Sileni V, . Bleomycin-based electrochemotherapy: Clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol 2009;16:191–9.
   PubMed Web of Science ®Google Scholar
• Gothelf A, Mir LM, Gehl J. Electrochemotherapy: Results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003;29:371–87.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Cuevas S, Barroso-Bravo S, Manza-Estrada J, Cristobal-Martinez L, Gonzalez-Rodriguez E. Electrochemotherapy in primary and metastatic skin tumors: Phase II trial using intralesional bleomycin. Arch Med Res 2001;32:273–6.
   PubMed Web of Science ®Google Scholar
• Gehl J, Geertsen PF. Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res 2000;10:585–9.
   PubMed Web of Science ®Google Scholar
• Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, Billard V, . Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. EJC Supplements 2006;4:14–25.
   Web of Science ®Google Scholar
• Domenge C, Orlowski S, Luboinski B, De BT, Schwaab G, Belehradek J, Jr., . Antitumor electrochemotherapy: New advances in the clinical protocol. Cancer 1996;77:956–63.
   PubMed Web of Science ®Google Scholar
• Hall SW, Strong JE, Broughton A, Frazier ML, Benjamin RS. Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol 1982;9:22–5.
   PubMed Web of Science ®Google Scholar
• Mathes DD. Bleomycin and hyperoxia exposure in the operating room. Anesth Analg 1995;81:624–9.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.
   PubMed Web of Science ®Google Scholar
• Mir LM, Belehradek M, Domenge C, Orlowski S, Poddevin B, Belehradek J, Jr., . [Electrochemotherapy, a new antitumor treatment: first clinical trial]. C R Acad Sci III 1991; 313:613–8.
   PubMed Web of Science ®Google Scholar
• Quaglino P, Mortera C, Osella-Abate S, Barberis M, Illengo M, Rissone M, . Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008;15:2215–22.
   PubMed Web of Science ®Google Scholar
• Tijink BM, De BR, Van Dongen GA, Leemans CR. How we do it: Chemo-electroporation in the head and neck for otherwise untreatable patients. Clin Otolaryngol 2006; 31:447–51.
   PubMed Web of Science ®Google Scholar
• Larkin JO, Collins CG, Aarons S, Tangney M, Whelan M, O’Reily S, . Electrochemotherapy: Aspects of preclinical development and early clinical experience. Ann Surg 2007; 245:469–79.
   PubMed Web of Science ®Google Scholar